Anacor Pharmaceuticals, Inc. Initiates Phase I Clinical Development for AN3365 – A Novel Antibiotic for the Treatment of Gram-Negative Infections

Bookmark and Share

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals today announced that it has dosed the first patient in a Phase I clinical study for AN3365, a novel boron-based, small-molecule drug candidate in development for the treatment of hospital infections caused by Gram-negative bacteria. The study will evaluate the safety, tolerability and pharmacokinetics of AN3365 in healthy volunteers.

MORE ON THIS TOPIC